Polysulfone capillary fiber forintraocular drug delivery: in vitro and in vivo evaluations

Author(s): Rahimy MH, PeymanGA, Chin SY, Golshani R, Aras C, et al.


Studies were conducted to investigate the usefulness of polysulfone capillary fiber (PCF) as a drug delivery device for intraocular applications. Carboxyfluorescein (CF) was used as a model drug to prepare PCF-dye devices for both in vitro and in vivo kinetic studies. For the in vitro study, PCF-CF devices were incubated in 0.1 M phosphate buffer, pH 7.4 at 37°C, and CF release was quantified at various times up to 5 weeks. In vitro results indicated a bi-phasic, sustained-release profile of CF from the PCF device for over 30 days. PCF-CF devices released 5% and 10% of their initial CF contents by the first and second day following incubation, respectively. By 10 days after incubation, approximately 50% of the dye content was released from the PCF-CF devices. The rate of dye release decreased thereafter, such that 65% and 90% of CF was released by 17 and 28 days after incubation, respectively. In a subsequent study, the in vivo kinetics of the PCF-CF device were determined in the rabbit eye. PCF-dye devices were prepared with the following CF formulations: 1) microsphere-incorporated CF; 2) lyophilized liposome-encapsulated CF; or 3) micronized CF powder. A PCF-dye device was implanted in the vitreous cavity, and fluorophotometry from the retina to the anterior chamber was performed at various times up to 45 days to quantify fluorescein level. At the conclusion of the study, eyes were enucleated and examined for histopathology. The time-course study showed fluorescein level for up to 45 days in the vitreous. The midvitreous concentration-time profile indicated a CF t1/2 of 10 and 30 days for the PCF-CF powder and PCF-CF liposome preparation, respectively. In contrast, the PCF device prepared with microsphere-incorporated CF showed fluorescein level with a t1/2 of less than one week in the vitreous. Histological examination of the eyes implanted with PCF or PCF-dye device showed no sign of ocular toxicity. Collectively, these results indicated that the PCF device is biocompatible and may be useful for the extended release of drugs in the posterior segment of the eye.

Similar Articles

Drug delivery to the posterior segment of the eye

Author(s): Lee TWY, RobinsonJR

Development andevaluation of prolonged release topical indomethacin formulations for ocularinflammation

Author(s): AdelliGR, Balguri SP, Punyamurthula N, Bhagav P, Majumdar S

Theblood-ocular barriers

Author(s): Cunha-Vaz J

Drug delivery to the retina: challenges and opportunities

Author(s): Duvvuri S,Majumdar S, Mitra AK

Ocularpreparations: the formulation approach

Author(s): Kaur IP, Kanwar M

Evaluation of topical hesperetin matrix filmfor back-of-the-eye delivery

Author(s): Adelli GR, Hingorani T, PunyamurthulaN, Balguri SP, Majumdar S

Ocular inserts - Advancement in therapy of eye diseases

Author(s): Kumari A, Sharma PK, Garg VK,Garg G

Ocular inserts for topical delivery

Author(s): SaettoneFM, Salminen L

Stability of benzocaine formulated in commercialoral disintegrating tablet platforms

Author(s): Köllmer M, Popescu C, Manda P,Zhou L, Gemeinhart RA

New methods of drug delivery

Author(s): Langer R

Iontophoretic drug delivery for the treatment ofscars

Author(s): Manda P, Angamuthu M, HiremathSR, Raman V, Murthy SN

Intravitreal sustained-releaseganciclovir

Author(s): Smith TJ, Pearson PA, BlandfordDL, Brown JD, Goins KA, et al.

Delivery of cefotaxime to the brain viaintranasal administration

Author(s): Manda P, Hargett JK, Kiran Vaka SR,Repka MA, Narasimha Murthy S

Biodegradable Intrascleral Implant for SustainedIntraocular Delivery of Betamethasone Phosphate

Author(s): Okabe J, Kimura H, Kunou N, OkabeK, Kato A, et al.

Delivery of ziconotide to cerebrospinalfluid via intranasal pathway for the treatment of chronic pain

Author(s): Manda P, Kushwaha AS, Kundu S,Shivakumar H, Jo SB, et al.

Episcleral implants for topotecandelivery to the posterior segment of the eye

Author(s): Carcaboso AM, Chiappetta DA,Opezzo JA, Höcht C, Fandiño AC, et al.